Logo image of CTOR

CITIUS ONCOLOGY INC (CTOR) Stock Fundamental Analysis

NASDAQ:CTOR - Nasdaq - US17331Y1091 - Common Stock - Currency: USD

0.9  +0.02 (+2.8%)

Fundamental Rating

1

Taking everything into account, CTOR scores 1 out of 10 in our fundamental rating. CTOR was compared to 561 industry peers in the Biotechnology industry. CTOR may be in some trouble as it scores bad on both profitability and health. CTOR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CTOR has reported negative net income.
CTOR Yearly Net Income VS EBIT VS OCF VS FCFCTOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 -5M -10M -15M -20M

1.2 Ratios

CTOR's Return On Assets of -23.37% is fine compared to the rest of the industry. CTOR outperforms 75.04% of its industry peers.
The Return On Equity of CTOR (-51.22%) is better than 63.64% of its industry peers.
Industry RankSector Rank
ROA -23.37%
ROE -51.22%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTOR Yearly ROA, ROE, ROICCTOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 -5 -10 -15 -20 -25

1.3 Margins

CTOR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTOR Yearly Profit, Operating, Gross MarginsCTOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2024

More info and screens

1

2. Health

2.1 Basic Checks

CTOR has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, CTOR has a worse debt to assets ratio.
CTOR Yearly Shares OutstandingCTOR Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 2M 4M 6M 8M
CTOR Yearly Total Debt VS Total AssetsCTOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -1.05, we must say that CTOR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.05, CTOR is in the better half of the industry, outperforming 60.43% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that CTOR is not too dependend on debt financing.
The Debt to Equity ratio of CTOR (0.09) is worse than 64.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -1.05
ROIC/WACCN/A
WACCN/A
CTOR Yearly LT Debt VS Equity VS FCFCTOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.39 indicates that CTOR may have some problems paying its short term obligations.
With a Current ratio value of 0.39, CTOR is not doing good in the industry: 94.47% of the companies in the same industry are doing better.
CTOR has a Quick Ratio of 0.39. This is a bad value and indicates that CTOR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CTOR (0.06) is worse than 98.04% of its industry peers.
Industry RankSector Rank
Current Ratio 0.39
Quick Ratio 0.06
CTOR Yearly Current Assets VS Current LiabilitesCTOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 500K 1M 1.5M 2M

More info and screens

1

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CTOR will show a very strong growth in Earnings Per Share. The EPS will grow by 50.53% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.24%
EPS Next 2Y37.9%
EPS Next 3Y50.53%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTOR Yearly Revenue VS EstimatesCTOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 20M 40M 60M 80M 100M
CTOR Yearly EPS VS EstimatesCTOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0 0.2 -0.2 0.4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTOR. In the last year negative earnings were reported.
Also next year CTOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTOR Price Earnings VS Forward Price EarningsCTOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTOR Per share dataCTOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

CTOR's earnings are expected to grow with 50.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.9%
EPS Next 3Y50.53%

More info and screens

0

5. Dividend

5.1 Amount

CTOR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CITIUS ONCOLOGY INC

NASDAQ:CTOR (5/22/2025, 12:24:58 PM)

0.9

+0.02 (+2.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner Change-41.75%
Ins OwnersN/A
Ins Owner Change0%
Market Cap64.39M
Analysts82.86
Price Target3.06 (240%)
Short Float %2.02%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.56
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.58
TBVpS-0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.37%
ROE -51.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.39
Quick Ratio 0.06
Altman-Z -1.05
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y21.24%
EPS Next 2Y37.9%
EPS Next 3Y50.53%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1152.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1152.71%
OCF growth 3YN/A
OCF growth 5YN/A